



**XELJANZ**<sup>®</sup>  
[tofacitinib citrate]

Trust isn't built in one day.  
**It may take up to 9.5 years**

**Reference:**

Wollenhaupt J, Lee EB, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. *Arthritis Res Ther.* 2019;21(1):89.



Breakthroughs that change patients' lives™

Trust isn't built in one day. **It may take up to 9.5 years\***

STUDIED IN  
**7,061**  
PATIENTS  
with moderate to severe RA<sup>3</sup>

**>22,800**  
PY of drug exposure  
(all doses; as of March 2017)<sup>1</sup>

**>260,000**  
PATIENTS  
have been prescribed Xeljanz worldwide  
(all indications as of June 2019)<sup>2</sup>

XELJANZ 5 mg BID is the only approved dosage for the treatment of RA. (Xeljanz (tofacitinib) latest approved Israeli prescribing information)

BID=twice daily; LTE=long-term extension; PY=patient-years; QD=once daily; RA=rheumatoid arthritis. 1. Cohen S, et al. Presented at the American College of Rheumatology Annual Scientific Meeting, October 19–24, 2018; Chicago, IL, USA. Abstract 963. 2. Data on file as of June 2019 Pfizer Inc., New York, NY. 3. SB Cohen et al, Long-term Safety of Tofacitinib up to 9.5 Years: A Comprehensive Integrated Analysis of the Rheumatoid Arthritis Clinical Development Program, ACR oct 18, Presentation No. 963.


\* Wollenhaupt J, Lee EB, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21(1):89.



Breakthroughs that change patients' lives™

# Xeljanz has three indications<sup>1</sup>

RA, PsA and UC and has been prescribed for more than 260,000 patients<sup>2</sup> worldwide



1. Xeljanz (tofacitinib) latest approved Israeli prescribing information
2. Pfizer data on file as of June 2019. Pfizer Inc. New York, NY



Breakthroughs that change patients' lives™